Coronavirus Update: RECOVERY Finds Kaletra Ineffective, Indian Company Joins Vaccine Race
Plus: Could Tweaks Boost Remdesivir Benefits?
A third set of authoritative results from UK trial ruled out use of AbbVie's HIV combination, plus Bharat Biotech to launch Phase I vaccine trials.
You may also be interested in...
High-profile experts including Anthony Fauci and Adrian Hill share views at the ICMR symposium on progressing safe COVID-19 vaccines backed by ethical trials executed with appropriate scientific rigor. Human challenge studies, "vaccine nationalism" and equitable access were among the key issues deliberated, while India committed to making its coronavirus vaccines and related capabilities available to the world.
More news from across the sector, including Novartis's non-profit pledge on medicines and Zydus Cadila commencing Phase I vaccine trial.
A five-day course will cost $2,340 for governments in developed countries and $3,120 for commercial payers. The US will get 100% of remdesivir manufactured by Gilead in July.